13F Holdings
中文EN

CSBR CHAMPIONS ONCOLOGY, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 771856 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.7%
TTM net income YoY-137.8%
TTM EPS YoY—
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—

Margins

Gross margin49.8%
Operating margin-1.7%
Net margin-1.8%
FCF margin-10.1%
EBITDA margin0.5%

Returns

ROE-29.8%
ROA-3.5%
ROIC (approx.)—
Asset turnover1.90x

Leverage & solvency

Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income5.04x
Accruals ratio14.0%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30FY20242024-04-30FY20232023-04-30FY20222022-04-30
Income statement
Revenue$59.42M$56.94M$50.16M$53.87M$49.11M
Cost of revenue$30.90M$28.39M$29.40M$29.53M$23.63M
Gross profit$28.52M$28.55M$20.75M$24.34M$25.48M
R&D expense$9.08M$6.83M$9.54M$11.54M$9.37M
SG&A expense$11.15M$9.34M$11.07M$10.24M$9.12M
Operating income-$1.14M$4.55M-$7.36M-$5.26M$607,000
Pretax income-$929,000$4.63M-$7.31M-$5.27M$583,000
Income tax$246,000-$75,000-$32,000$68,000$35,000
Net income-$1.18M$4.70M-$7.28M-$5.33M$548,000
EBITDA$260,000$6.15M-$5.46M-$3.16M$2.11M
EPS (basic)-0.080.34-0.54-0.390.04
EPS (diluted)-0.080.33-0.54-0.390.04
Weighted avg. shares (diluted)13.83M14.27M13.55M13.54M14.16M
Balance sheet
Cash & equivalents$4.87M$9.79M$2.62M$10.12M$9.01M
Receivables$13.18M$11.20M$9.53M$8.01M$9.51M
Current assets$19.22M$22.36M$13.64M$19.46M$19.66M
PP&E, net$3.53M$4.38M$5.72M$7.19M$7.13M
Goodwill$335,000$335,000$335,000$335,000$335,000
Total assets$26.99M$32.34M$26.13M$34.31M$35.38M
Current liabilities$19.92M$23.85M$21.54M$21.73M$17.48M
Total liabilities$22.92M$28.57M$28.04M$29.68M$26.28M
Shareholders' equity$3.94M$3.77M-$1.90M$4.64M$9.10M
Shares outstanding13.89M13.78M13.59M13.54M13.52M
Cash flow statement
Operating cash flow-$4.47M$7.39M-$6.14M$3.97M$6.50M
Capital expenditure$564,000$389,000$836,000$2.87M$2.38M
Free cash flow-$5.04M$7.00M-$6.97M$1.10M$4.11M
Investing cash flow-$540,000-$389,000-$836,000-$2.87M-$2.38M
Financing cash flow$99,000$170,000-$527,000$11,000$207,000
Depreciation & amortization$1.40M$1.60M$1.90M$2.10M$1.50M
Stock-based compensation$1.24M$654,000$1.12M$864,000$912,000
Share buybacks—$0$634,000$74,000$0

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.